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Previously, we reported that epigallocatechin 3-O-gallate (EGCg) has growth-in-
hibitory effect on clinical isolates of Candida species. In this study, we investigat-
ed the antifungal activity of EGCg and antifungal agents against thirty-five of der-
matophytes clinically isolated by the international guidelines (M38-A2). All 
isolates exhibited good susceptibility to EGCg (MIC50, 2-4 µg/mL, MIC90, 4-8 µg/
mL, and geometric mean (GM) MICs, 3.36-4 µg/mL) than those of fluconazole 
(MIC50, 2-16 µg/mL, MIC90, 4-32 µg/mL, and GM MICs, 3.45-25.8 µg/mL) and 
flucytosin (MIC50, MIC90, and GM MICs, >64 µg/mL), although they were less 
susceptible to other antifungal agents, such as amphotericin B, itraconazole, and 
miconazole. These activities of EGCg were approximately 4-fold higher than 
those of fluconazole, and were 4 to 16-fold higher than flucytosin. This result indi-
cates that EGCg can inhibit pathogenic dermatophyte species. Therefore, we sug-
gest that EGCg may be effectively used solely as a possible agent or combined 
with other antifungal agents for antifungal therapy in dermatophytosis.
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Dermatophytosis, mycotic infections, is one of among the most common and 
widespread worldwide infectious diseases and represent an important public health 
problem yet unresolved. It can be caused by keratinophilic and keratinolytic der-
matophytes, particularly Microsporum canis (M. canis), Trichophyton mentagro-
phytes (T. mentagrophytes), and Trichophyton rubrum (T. rubrum).1-8 Although 
many antifungal agents have been developed during the last decades and have be-
come available for dermatophytosis, they are confined to a relatively few chemical 
groups. In addition, the occurrence of resistance or side effects in clinically isolat-
ed strains leads to failure in the treatment of mycosis.9 Thus, effective antifungal 
agents, which are highly effective and safe, are necessary and important for the ex-
termination of antibiotic-susceptible and -resistant strains. 
In recent years, there are several reports on antifungal activity of natural prod-
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All standard antifungal susceptibility testing was per-
formed according to the document M38-A2, published by 
the Clinical and Laboratory Standards Institute (CLSI; for-
merly National Committee for Clinical Laboratory Stan-
dards, or NCCLS).25 As described in our previous study,24 
fungal cell suspensions were spectrophotometrically stan-
dardized to a turbidity equivalent to that of a 0.5 McFarland 
standard. The suspensions were prepared from 10 to 14 day 
cultures grown on PDA, and the density was 2×105 colony 
forming unit (cfu)/mL. The final inoculum was adjusted to 
approximately 2×104 cfu/mL. All tests were performed in 
96-wells plate. Aliquots of one hundred microliters of sus-
pension were inoculated into each well containing diluted 
EGCg or five antifungal agents. Drug-free controls and 
growth controls were included for each assay. The plates 
were incubated at 35°C and read visually after 4 to 7 days. 
The MICs of EGCg and five antifungal agents were defined 
as the lowest drug concentrations that resulted in a 50% and 
90% reduction in growth compared with that of the drug-
free growth control, as recommended by the CLSI.25 Geo-
metric mean (GM) MICs were determined to facilitate com-
parisons of the activities of EGCg and five antifungal agents. 
Data shown are from three separate tests and were analyzed 
statistically by calculating means and S.D of the means. 
MICs were determined after 7 days of culture because 
the growth of some strains for 4 days was insufficient. 
MIC50 and MIC90, the MIC values that inhibited 50 and 90% 
of isolate growth, as well as the MIC range of EGCg and 
antifungal agents, AMPH, FLCZ, 5FC, ITCZ, and MCZ, 
against thirty-five clinical isolates of three dermatophyte spe-
cies are summarized in Table 1. Although, the susceptibili-
ties were different depending on the types of strains and 
species, the dermatophytes used in this study were in gener-
al susceptible to EGCg. The MIC ranged from 0.5 to 16 µg/
mL with all isolates, and the GM MICs were 3.69 µg/mL in 
M. canis, 3.80 µg/mL in T. mentagrophytes, and 3.36 µg/
mL in T. rubrum species. Moreover, all isolates exhibited 
better susceptibilities to EGCg (MIC50, 2-4 µg/mL, MIC90, 
4-8 µg/mL, and GM MICs, 3.36-4 µg/mL) than to FLCZ 
(MIC50, 2-16 µg/mL, MIC90, 4-32 µg/mL, and GM MICs, 
3.45-25.8 µg/mL) and 5FC (MIC50, MIC90, and GM MICs, 
>64 µg/mL). As shown in Table 1, however, they were slight-
ly less susceptible to other antifungal agents. The GM MICs 
of EGCg were approximately 7- to 17-fold in M. canis, 3- 
to 17-fold in T. mentagrophytes, and 1- to 19-fold in T. ru-
brum higher than those of FLCZ and 5FC. Among EGCg 
and five antifungal agents tested in this study, only the GM 
ucts.10-14 Green tea polyphenols have been reported to have 
an antimicrobial effect against oral, intestinal, and food-
borne bacteria, antitoxicity against various bacterial haemo-
lysins, and antiviral activity.15-20 The main polyphenol com-
ponent of green tea, epigallocatechin 3-O-gallate (EGCg), 
with direct antibacterial properties, can decrease bacterial 
invasion by inhibition of bacterial gelatinase activities.21,22 
Okubo, et al.23 reported that black tea extract inhibited the 
growth of Trichophyton mentagrophytes and Trichophyton 
rubrum, but it was not by EGCg only. Recently, we showed 
that EGCg has growth-inhibitory effect on clinical isolates 
of Candida species, but not on dermatophytes.24 In this study, 
therefore, we investigated the antifungal activity of EGCg 
and five antifungal agents, such as amphotericin B, flucyto-
sin, fluconazole, itraconazole, and miconazole against clini-
cal isolates of dermatophyte species by determination of 
minimum inhibitory concentration (MIC).  
As described in our previous study,24 all tests performed in 
RPMI-1640 medium (Sigma, St. Louis, MO, USA) with L-
glutamine and low glucose (2 mg/mL), without phenol red 
and sodium bicarbonate, buffered with 0.165 M 3-(N-mor-
pholino) propanesulfonic acid, pH adjusted to 7.0 with 
NaOH and sterilized. EGCg was also kindly supplied by 
Pharma Foods International Co. Ltd. (Kyoto, Japan), and the 
purity of EGCg exceeded 97%, and the concentration of 
EGCg from 0.06 to 32 µg/mL was used. Dry plates including 
five antifungal agents such as amphotericin B (AMPH; 0.03-
16 µg/mL), flucytosin (5FC; 0.125-64 µg/mL), fluconazole 
(FLCZ; 0.125-64 µg/mL), itraconazole (ITCZ; 0.015-8 µg/
mL), and miconazole (MCZ; 0.06-32 µg/mL), were pur-
chased from Eiken Chemical Co., LTD. (Tokyo, Japan). 
Thirty-five clinical isolates of three dermatophyte species 
(thirteen M. canis strains; IFM 41048, 41054, 41061, 41115, 
46053, 53789, 53817, 54153, 54155, 54156, 54157, 54158, 
54199, eleven T. mentagrophytes strains; IFM 46600, 46609, 
46634, 47174, 47176, 53815, 53931, 55190, 55191, 55192, 
55193, and eleven T. rubrum strains; IFM 45623, 45625, 
47162, 47163, 47164, 47165, 47166, 47167, 47170, 55188, 
55189), and three Candida strains, Candida albicans (ATCC 
90028), C. parapsilosis (ATCC 90018), and C. krusei 
(ATCC 6258) for quality control were obtained from the Re-
search Center for Pathogenic Fungi and Microbial Toxicoses, 
Chiba University in Japan. All dermatophytes were cultured 
on potato dextrose agar (PDA) slant at 35°C for 10 to14 
days, whereas three Candida strains were cultured on PDA 
slant at 35°C for 24 hours and passaged twice at a 48 hours 
interval before use.
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of EGCg under an in vitro condition, and we demonstrated 
in this study, potent antifungal activity of EGCg against clin-
ical isolates of pathogenic dermatophytes in vitro compared 
with the other antifungal agents tested, FLCZ and 5FC. 
Among the dermatophyte species tested, T. rubrum was the 
most susceptible to EGCg: they were more susceptible than 
to 5FC and were similar to those of FLCZ, although they 
were less susceptible than to ITCZ, MCZ, and AMPH. GM 
MICs of EGCg towards M. canis and T. mentagrophytes 
were lower and they were more susceptible to EGCg than to 
FLCZ and 5FC. These results suggest that EGCg can be 
used as an antifungal agent or adjuvant with antifungal 
agents in dermatophytosis and can be applied in the field of 
antifungal therapy, although the dermatophytes were slightly 
less susceptible to it than to other antifungal agents, such as 
ITCZ, MCZ, and AMPH. Furthermore, EGCg does not de-
velop resistances and it may avoid the side effects.21,24,30,31 
In conclusion, it would seem that EGCg may be used as 
an antifungal agent solely or in combination with other an-
tifungal agents as previously reported24,32 or as an adjuvant. 
Although, higher concentration of EGCg than that used in 
the present study may be needed to treat human dermato-
phytosis patients, the mechanism of antifungal effects in 
dermatophytes has not yet been defined, and more studies 
such as in vivo or ex vivo experiments are needed to verify 
these possibilities. Nevertheless, the present study showed 
MICs of FLCZ were different among the dermatophyte 
species tested; As shown in Table 1, M. canis (25.84 µg/mL), 
T. mentagrophytes (11 µg/mL), and T. rubrum (3.45 µg/mL). 
Among the antifungal agents tested, ITCZ (MIC50, <0.125-
0.5 µg/mL, MIC90, <0.25-1 µg/mL, and GM MICs, 0.14-
0.58 µg/mL) had the strongest antifungal activities regard-
less of the strain.
Recently, Weitzman and Summerbell1 reported that pro-
liferation of new classes of drugs, such as terbinafine and 
itraconazole, represents the most remarkable trend in der-
matophytosis therapy. Itraconazole have been used effec-
tively.26 However, treatment with these agents for prolonged 
period requires periodic monitoring of liver activity.27 More-
over, these agents may have drug interactions with other 
medications.28 In this context, therefore, new antifungal 
agents from natural products could be useful alternatives 
for the treatment of dermatophytosis, because they have 
some advantages, such as reduced risk of side-effects and 
lower cost, and there has recently been growing interest in 
the use of medicinally important plants and their com-
pounds to cure some diseases.
EGCg, a main component of tea catechins present in 
green tea, is known to possess antibacterial activity and the 
effects of certain antibiotics.29-31 Hirasawa and Takada32 re-
ported the susceptibility of Candida albicans to catechins 
including EGCg. Recently, we examined anticandidal effect 
Table 1. Antifungal Activities of EGCg and Antifungal Agents Against Clinical Isolates of Dermatophytes
Species (no. of isolates) Antifungal drug
MIC data (µg/mL)
MIC range MIC50 MIC90 Geometric mean MIC
Microsporum canis (13)
EGCG 0.5-8 2  8 3.69
AMPH 0.5-4    0.5  2 1
5FC >64 >64 >64 >64
FLCZ    16-32 16 32 25.84
ITCZ 0.5-1    0.5   1 0.58
MCZ    1-2 1   2 1.38
Trichophyton 
  mentagrophytes (11)
EGCG    2-8 4   4 3.80
AMPH 0.5-1 1   1 0.80
5FC >64 >64 >64 >64
FLCZ      2-16 8 16 11
ITCZ    0.06-0.25        0.125 0.25 0.14
MCZ 0.125-0.1    0.5   1 0.57
Trichophyton rubrum (11)
EGCG      1-16 2   4 3.36
AMPH 0.5-1    0.5   1 0.64
5FC >64 >64 >64 >64
FLCZ      1-16 2      4 3.45
ITCZ 0.125-0.5        0.125           0.25 0.18
MCZ   0.06-1      0.25         0.5 0.38
EGCG, Epigallocatechin 3-O-gallate; AMPH, amphotericin B; 5FC, flucytosine; FLCZ, fluconazole; ITCZ, itraconazole; MCZ, miconazole.
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15. Sakanaka S, Kim MJ, Taniguchi M, Yamamoto T. Antibacterial 
substances in Japanese green tea extract against Streptococcus mu-
tans, a cariogenic bacterium. Agric Biol Chem 1989;53:2307-11.
16. Hirasawa M, Takada K, Makimura M, Otake S. Improvement of 
periodontal status by green tea catechin using a local delivery sys-
tem: a clinical pilot study. J Periodontal Res 2002;37:433-8.
17. Ahn YJ, Sakanaka S, Kim MJ, Kawamura T, Fujisawa T, Mitsuo-
ka T. Effect of green tea extract on growth of intestinal bacteria. 
Microb Ecol Health Dis 1990;3:335-8.
18. Hara Y, Ishigami T. Antibacterial activities of tea polyphenols 
against foodborne pathogenic bacteria. J Jpn Soc Food Sci Tech 
1989;36:996-9.
19. Okubo S, Ikigai H, Toda M, Shimanura T. The anti-haemolysin 
activity of tea and coffee. Lett Appl Microbiol 1989;9:65-6.
20. Nakane H, Ono K. Differential inhibitory effects of some catechin 
derivatives on the activities of human immunodeficiency virus re-
verse transcriptase and cellular deoxyribonucleic and ribonucleic 
acid polymerases. Biochemistry 1990;29:2841-5. 
21. Blanco AR, La Terra Mule S, Babini G, Garbisa S, Enea V, Rusci-
ano D. (-)Epigallo- catechin-3-gallate inhibits gelatinase activity of 
some bacterial isolates from ocular infection, and limits their inva-
sion through gelatine. Biochim Biophys Acta 2003;1620:273-81.
22. Sudano Roccaro A, Blanco AR, Giuliano F, Rusciano D, Enea V. 
Epigallocatechin-gallate enhances the activity of tetracycline in 
staphylococci by inhibiting its efflux from bacterial cells. Antimi-
crob Agents Chemother 2004;48:1968-73.
23. Okubo S, Toda M, Hara Y, Shimamura T. [Antifungal and fungi-
cidal activities of tea extract and catechin against Trichophyton]. 
Nippon Saikingaku Zasshi 1991;46:509-14.
24. Park BJ, Park JC, Taguchi H, Fukushima K, Hyon SH, Takatori K. 
Antifungal susceptibility of epigallocatechin 3-O-gallate (EGCg) 
on clinical isolates of pathogenic yeasts. Biochem Biophys Res 
Commun 2006;347:401-5.
25. Clinical and Laboratory Standards Institute, Reference method for 
broth dilution antifungal susceptibility testing of filamentous fun-
gi; Approved standard-second edition, CLSI document. Wayne, 
PA, USA: CLSI/NCCLS; 2008. p.M38-A2.
26. Tejasvi T, Sharma VK, Sethuraman G, Singh MK, Xess I. Inva-
sive dermatophytosis with lymph node involvement in an immu-
nocompetent patient. Clin Exp Dermatol 2005;30:506-8.
27. Zapata Garrido AJ, Romo AC, Padilla FB. Terbinafine hepatotox-
icity. A case report and review of literature. Ann Hepatol 2003;2: 
47-51. 
28. Huang DB, Ostrosky-Zeichner L, Wu JJ, Pang KR, Tyring SK. 
Therapy of common superficial fungal infections. Dermatol Ther 
2004;17:517-22.
29. Higdon JV, Frei B. Tea catechins and polyphenols: health effects, 
metabolism, and antioxidant functions. Crit Rev Food Sci Nutr 
2003;43:89-143.
30. Jodoin J, Demeule M, Beliveau R. Inhibition of the multidrug re-
sistance P-glycoprotein activity by green tea polyphenols. Bio-
chim Biophys Acta 2002;1542:149-59.
31. Stapleton PD, Taylor PW. Methicillin resistance in Staphylococ-
cus aureus: mechanisms and modulation. Sci Prog 2002;85:57-72.
32. Hirasawa M, Takada K. Multiple effects of green tea catechin on 
the antifungal activity of antimycotics against Candida albicans. J 
Antimicrob Chemother 2004;53:225-9.
that EGCg can be applied as an alternate antifungal agent to 
overcome resistance to other reported antifungal agents, 
and it may be effectively used as a possible agent or adju-
vant for the treatment of dermatophytosis.
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